2020 SASB & GRI Content Indices

Code

Accounting Metric

Disclosure

Safety of Clinical Trial Participants

HC-BP-210a.1

Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials

Biogen has a Global Pharmacovigilance (PV) team comprised of medical and scientific professionals with extensive safety and/or clinical or healthcare experience who are trained in PV and worldwide health authority regulations relevant to medicinal product safety. 

Biogen’s safety signal management processes, combined with our robust safety governance framework, allow Biogen to determine if new safety information on our products (a ‘signal’) poses a risk to patients and how best to manage, mitigate and communicate the risk. All safety and benefit/risk decisions for marketed and investigational products are made at the Safety Monitoring Committee (SMC). The Safety team collaborates with Regulatory Affairs to communicate product information in a timely, transparent and accurate manner to regulatory agencies across the globe.

In addition to complying with our company’s global standards, the conduct of our clinical trials adheres to the International Council for Harmonisation Good Clinical Practice (ICH GCP) standards and to the principles that have their origin in the Declaration of Helsinki.     

Each country has its own regulatory authority with its own regulations, or laws, for conducting a clinical trial. The regulatory authority reviews and approves the protocol and ensures that the clinical trial follows national regulations.

An Institutional Review Board (IRB) or Ethics Committee (EC) is an independent committee that includes medical, scientific and non-scientific members, whose responsibility is to protect the rights, welfare, safety and well-being of clinical trial participants. Each clinical trial location is monitored by a specific IRB / EC. It is responsible for reviewing all clinical trials as well as conducting ongoing reviews of active clinical trials.

For more information, please visit our clinical trials webpage.

 HC-BP-210a.2

Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)

Biogen is committed to transparent Environmental, Social, and Governance reporting and intends to expand its SASB disclosure in the following year.

 HC-BP-210a.3

Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries

Biogen did not sustain any monetary losses in the reporting period as a result of legal proceedings associated with the conduct as described.

Biogen discloses all material legal and regulatory proceedings in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Access to Medicines

HC-BP-240a.1

Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index

Early-Onset Spinal Muscular Atrophy (SMA) is a priority disease as defined by the Access to Medicine Index.

In 2020 we completed a one-year pilot program in India to help expand access to SPINRAZA for individuals in need of treatment. The SPINRAZA Individual Patient Humanitarian Aid Access Program (SIPHAP) provided SPINRAZA free of charge to program participants, who were selected by an independent committee of medical experts.

Developed in collaboration with Direct Relief, SIPHAP was designed after months of considerable work including research, interviews, on-the-ground assessments of infrastructure and facilities, and training for the clinicians participating in the program. 

SIPHAP initially launched with 24 patients across 4 public hospitals in India, with 2020 expansion put on hold due to the COVID-19 pandemic. Despite pandemic challenges, all patients received all recommended doses throughout 2020. We are currently exploring the potential for future expansion within India and other countries. 

SPINRAZA is approved in more than 50 countries, including low- and middle-income countries, with formal reimbursement in 40 countries. Our policy to promote access to SPINRAZA will help inform our approach to our broader portfolio of therapies.

HC-BP-240a.2

List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)

Biogen has no products on the WHO List of Prequalified Medicinal Products

Affordability & Pricing

HC-BP-240b.1

Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period

Biogen does not comment on confidential legal matters

HC-BP-240b.2

Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year

In 2020 we saw a list price increase of 5.190% and a net price decrease of 0.273% across our U.S. product portfolio compared to the previous year.

In addition, Biogen’s anti-TNF biosimilars may have provided healthcare savings of approximately €2.4 billion in 2020 in the markets where they are sold. This savings may provide headroom for new innovative therapies to come to market.

We regularly review our pricing strategy and prioritize patient access to our therapies. We have a value-based contracting program designed to align the price of our therapies to the value our therapies deliver to patients. We also work with regulators, clinical researchers, ethicists, physicians and patient advocacy organizations and communities, among others, to determine how best to address requests for access to our investigational therapies in a manner that is consistent with our patient-focused values and compliant with regulatory standards and protocols. Additional information is available here:

2020 10-K

Biogen Pricing Principles

HC-BP-240b.3

Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year

Biogen’s anti-TNF biosimilars may have provided healthcare savings of approximately €2.4 billion in 2020 in the markets where they are sold. This savings may provide headroom for new innovative therapies to come to market.

We regularly review our pricing strategy and prioritize patient access to our therapies. We have a value-based contracting program designed to align the price of our therapies to the value our therapies deliver to patients. We also work with regulators, clinical researchers, ethicists, physicians and patient advocacy organizations and communities, among others, to determine how best to address requests for access to our investigational therapies in a manner that is consistent with our patient-focused values and compliant with regulatory standards and protocols.

Additional information is available here:

2020 10-K

Biogen Pricing Principles

Drug Safety

HC-BP-250a.1

List of products listed in the U.S. Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database

There were no listings relevant to Biogen’s products on the FDA’s MedWatch Safety Alerts for Human Medical Products database in 2020.

HC-BP-250a.2

Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System

All information related to fatalities associated with Biogen products are available via FDA Adverse Event Reporting website. 

HC-BP-250a.3

Number of recalls issued; total units recalled

1 Class II (VUMERITY recall initiated December 2020, still in progress) / 1 Class III (TECFIDERA initiated June 2020 closed February 2021)

HC-BP-250a.4

Total amount of product accepted for takeback, reuse, or disposal

Due to the low volume of its products, at this time, Biogen does not manage a formal product takeback, reuse or disposal program. Per regulatory requirements, Biogen participates in several product takeback programs across various U.S. states or counties, and several other countries. In addition, Biogen provides guidance on disposal methods of its products.

HC-BP-250a.5

Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type

Biogen did not receive any FDA enforcement actions associated with warning letters, seizures, recalls or consent decrees in 2020. 

Counterfeit Drugs

HC-BP-260a.1

Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting

Counterfeiting is now the largest criminal enterprise in the world, accounting for more than 3% of global trade. Not one industry is exempt from this growing threat. Patient safety is our number one priority and we take the issue of counterfeit, falsified drugs very seriously. The main goal of our Product Security function is to implement a holistic strategy in order to proactively identify, mitigate and manage illicit trade risks that could be impacting reputation and trust, and most importantly jeopardizing the health and safety of patients that take our drugs. We aim to disrupt diversion, counterfeiting, theft and other nefarious activities through the following 5 pillars: 

- Threat Assessments: Identifying, assessing and mitigating risks and vulnerabilities across the supply chain

- Auditing: Audit supply chain partners to ensure industry best practice requirements are met regarding product security

- Monitoring: Monitor markets, channels, supply chain, customer complaints and other network elements to detect illicit trade signals and potential threats to supply chain resiliency and robustness

- Investigations: Respond to incidents with robust investigation and enforcement capability, including legal actions to stop and deter illicit trade

- Product Security: Ensure we have the appropriate level of security measures for products and supply chain nodes in order to minimize the threat of counterfeits, diversions and thefts for the purpose of ensuring patient safety

In addition to the above, a majority of our global production is serialized, meeting all global compliance requirements on serialization including the U.S. and the European Union (EU). Whenever we serialize, we also aggregate the serialization information to enable Track&Trace. We have implemented Track&Trace capabilities at our main distribution sites, beyond compliance requirements, to provide additional elements of traceability.

 

HC-BP-260a.2

Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products

Biogen employs quality governed processes to manage the handling of suspect or illegitimate medicinal products: Upon detecting a potential or known product security risk, the event is captured as a complaint into the TrackWise system for formal tracking. Furthermore, there are requirements on segregation of product and the investigation process. Once the product is physically acquired, the technical product complaints group performs an investigation to verify if the product is genuine or falsified. If determined that the suspected product is falsified, potentially falsified or high risk of being falsified, a DMRB (global distributed material review board) must be completed, defining further specific market actions and communications. As necessary, all impacted competent authorities and impacted distribution partners are then notified. Once a case is closed, Biogen notifies the applicable authorities and impacted trading partners.

In addition to the above internal processes, Biogen also participates in industry-wide systems and processes utilizing serialization data. For example, in the EU, each medication is verified against the list of list of serial numbers in circulation, prior to dispensing. Medicines shall not be dispensed if the number cannot be verified.  If a medicine’s serial number cannot be verified, a notification, called an alert, is electronically generated by the relevant National Medicines Verification Organization (NMVO) and shared with TraceLink, Biogen’s Serialization System. Biogen reviews these alerts and resolves them in correspondence with the relevant NMVO. Serialization alerts that indicate suspect or illegitimate product will trigger the internal process described above.

HC-BP-260a.3

Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products

Biogen did not take any actions in the reporting period that led to raids, seizure, arrests and/or filing of criminal charges related to counterfeit products

Ethical Marketing

HC-BP-270a.1

Total amount of monetary losses as a result of legal proceedings associated with false marketing claims

Biogen did not sustain any monetary losses in the reporting period as a result of legal proceedings associated with the conduct as described

Biogen discloses all material legal and regulatory proceedings in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

HC-BP-270a.2

Description of codes of ethics governing promotion of off-label use of products

Please visit our Access page for a description of Biogen’s approach to off-label use.

Employee Recruitment, Developing & Retention

HC-BP-330a.1

Discussion of talent recruitment and retention efforts for scientists and research and development personnel

In 2020 we hired over 380 individuals into R&D globally and over 130 scientists across Biogen, composed of 76 scientists in the R&D organization.

Biogen recently announced a $200 million investment to build a new gene therapy manufacturing facility at our Research Triangle Park (RTP) manufacturing campus in North Carolina.

We expanded our engagement with conferences/programs that allow us to increase our R&D brand within underrepresented communities, including: Women of Color in Pharma (WOCIP), American Women in Science (AWIS), (BVN Partnership).

HC-BP-330a.2

(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid level managers, (c) professionals, and (d) all others

Total Turnover Rate: 9.00%

- Voluntary Turnover Rate: 7.20%

- Involuntary Turnover Rate: 1.80%

Supply Chain Management

HC-BP-430a.1

Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients

Biogen outsources anywhere from 10 to 15% of our external supplier audits. We perform the vast majority of our audits through our own audit program using outsourced support or use depending on the type of service provided, risk and availability.

Business Ethics

HC-BP-510a.1

Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery

Biogen did not sustain any monetary losses in the reporting period as a result of legal proceedings associated with the conduct as described.

Biogen discloses all material legal and regulatory proceedings in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

HC-BP-510a.2

Description of code of ethics governing interactions with healthcare professionals

We comply with the Pharmaceutical Research and Manufacturers of America’s (PhRMA) Code on Interactions with Healthcare Professionals.

See our Code of Business Conduct section on Interactions with Healthcare Professionals.

Activity Metrics

HC-BP-000.A

Number of patients treated

Our portfolio of 5 MS disease-modifying therapies has helped improve the lives of more than 1 million patients worldwide, and we have more than 25 active clinical trials. Additionally, Biogen ended 2020 with roughly 11,000 patients on SPINRAZA, including through our clinical studies and expanded access program

Available in the EU, approximately 240,000 patients across 15 indications in over 25 countries relied on our anti-TNF biosimilars in 2020, which represented a patient growth of 15% year-over-year. Through the end of 2020, since the inception of our biosimilars unit, we have shipped over 20 million doses with uninterrupted product supply to patients in over 25 European countries.

HC-BP-000.B

Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)

The number of drugs actively on the market is 10.

We closed 2020 with a pipeline that included clinical programs:

•Number in Phase 1 = 14

•Number in Phase 2 = 9

•Number in Phase 3 = 10

We now have 10 programs either in Phase 3 or filed with regulatory agencies, including in Alzheimer’s disease, neuropsychiatry, amyotrophic lateral sclerosis (ALS) and ophthalmology. In 2020, we added or advanced 12 clinical programs, bolstering our early- and late-stage pipelines through both internal development and collaborations with leading neuroscience companies, including Sangamo Therapeutics, Inc. (Sangamo), Denali Therapeutics Inc. (Denali) and Sage Therapeutics, Inc. (Sage). We believe we are well positioned for future growth with readouts expected in 2021 from eight clinical programs, of which four are pivotal readouts.

More information on our product portfolio and pipeline is provided on our website.

Values are as of December 31, 2020.

GRI Content Index

GRI Indicator

Description

Reference

SDG Alignment

GRI 102: GENERAL DISCLOSURES 2016

Organizational Profile

102-1

Name of the organization

Biogen Inc.

 

102-2

Activities, brands, products, and services

Message from the CEO– 2020 Year in Review

Item 1., Business, 2020 Form 10-K, pages 1-28

 

102-3

Location of headquarters

Corporate Headquarters: Cambridge, Massachusetts (U.S.)

 

102-4

Location of operations

Pharmaceutical Operations & Technology

Item 2., Properties, 2020 Form 10-K, pages 47-48

 

102-5

Ownership and legal form

Board of Directors

Corporate Governance Documents

 

102-6

Markets served

Item 1., Business, 2020 Form 10-K, pages 6-9

 

102-7

Scale of the organization

Highlights – 2020 Annual Report

Item 1., Business, 2020 Form 10-K, pages 1-28

Item 6., Selected Financial Data, 2020 Form 10-K, page 51

 

102-8

Information on employees and other workers

Item 1., Business, 2020 Form 10-K, pages 26-31

 

102-9

Supply chain

Item 1., Business, 2020 Form 10-K, pages 25-26

12

102-10

Significant changes to the organization and its supply chain

Item 1., Business, 2020

Form 10-K, pages 2-3

 

102-11

Precautionary Principle or approach

Biogen applies the precautionary approach by achieving carbon neutrality, ensuring the safety of patients and performing detailed risk analyses related to its operations.

 

102-12

External initiatives

Principles, Policies & Positions

Environment Sections – 2020 Year in Review

 

102-13

Membership of associations

Environment Sections – 2020 Year in Review

Biogen membership associations:

RE100 Company – Global initiative uniting more than 290 influential businesses committed to 100% renewable electricity

 

Pharmaceutical Supply Chain Initiative (PSCI) – Organization of leading global pharmaceutical companies focused on increasing the capabilities and responsibility of our supply chains

Pharmaceutical Product Stewardship Work Group – Association for drug and sharp manufacturers and marketers formed to address the disposal of unused and unwanted pharmaceutical products.

EV100 – The World Economic Forum engages the foremost political, business, cultural and other leaders of society to shape global, regional and industry agendas.

Biopharma Sustainability Roundtable – A sector-specific platform designed to connect and support senior biotech and pharma executives in driving their Biopharma sustainability agendas forward.

CSR Board – Confidential, vendor‑free membership organization for people leading corporate social responsibility at the world’s biggest companies.

WBCSD – Global, CEO-led organization of over 200 leading businesses working together to accelerate the transition to a sustainable world.

UNGC – Voluntary initiative based on CEO commitments to implement universal sustainability principles and to take steps to support UN goals.

WEF – The World Economic Forum engages the foremost political, business, cultural and other leaders of society to shape global, regional and industry agendas.

 

102-14

Statement from senior decision-maker

Message from the CEO - 2020 Year in Review

 

102-15

Key impacts, risks, and opportunities

Item 1A., Risk Factors, 2020 Form 10-K, pages 33-47

TCFD Report - 2020 Year in Review

 

Ethics and Integrity

102-16

Values, principles, standards, and norms of behavior

Code of Business Conduct 

Principles, Policies & Positions

 

102-17

Description of internal and external mechanisms for: seeking advice

Code of Business Conduct

 

102-18

Governance structure

Executive Leadership

Board of Directors

Corporate Governance Documents

 

102-30

Highest governance body’s role

Code of Business Conduct 

Sustainability Policy

Environmental Health and Safety Policy 

 

102-33

Process for communicating critical concerns to the highest governance body

Code of Business Conduct (Values in Action) 

 

Stakeholder Engagement

102-40

List of stakeholder groups

Reporting Section - 2020 Year in Review

 

102-41

Collective bargaining agreements

Approximately 13.1 percent of Biogen’s employees are under a collective bargaining agreement using a time-weighted average basis.

 

102-42

Identifying and selecting stakeholders

Reporting Section - 2020 Year in Review

 

102-43

Approach to stakeholder engagement

Reporting Section - 2020 Year in Review

 

102-44

Key topics and concerns raised

Reporting Section - 2020 Year in Review

 

Reporting Practice

102-45

Entities included in the consolidated financial statements

All major entities are included in the boundaries of this report.

See the 2020 Form 10-K

 

102-46

Defining report content and topic boundaries

Reporting Section - 2020 Year in Review

 

102-47

List of material topics

Reporting Section - 2020 Year in Review

 

102-48

Restatements of information

No restatements were made

 

102-49

Changes in reporting

No significant changes from the previous reporting period

 

102-50

Reporting period

Data covers fiscal year ending December 31, 2020. Some activities from 2021 are also included.

 

102-51

Date of most recent report

April 23, 2021

 

102-52

Reporting cycle

We report on an annual basis

 

102-53

Contact point for questions regarding the report

Biogen Media contact:

public.affairs@biogen.com

Biogen Reputation & Responsibility contact:

responsibility@biogen.com

 

102-54

Claims of reporting in accordance with the GRI Standards

This report has been prepared in accordance with the GRI Standards: Core option

 

102-55

GRI Content Index

GRI Content Index

 

102-56

External assurance

ERM CVS Independent Assurance Statement to Biogen Inc. 

 

GRI 103: TOPICS AND TOPIC BOUNDARIES

103-1

Explanation of the material topic and its boundary

Reporting Section - 2020 Year in Review  

103-2

The management approach and its components

Our Purpose Section 2020 - Year in Review 

 

103-3

Evaluation of the management approach

Consolidated Financial Statements, 2020 Form 10-KERM CVS Independent Assurance Statement to Biogen Inc.

 

GRI 200-400 TOPIC-SPECIFIC DISCLOSURES 2016

Economic

Economic Performance

201-1

Direct economic value generated and distributed

GAAP audited financial statements, 2020 Annual Report

Item 6., Selected Financial Data, 2020 Form 10-K, page 51, F-75-76

 

201-2

Financial implications and other risks and opportunities due to climate change

TCFD Report - 2020 Year in Review

2020 CDP Climate Change disclosure

 

201-3

Defined benefit plan obligations and other retirement plans

Consolidated Financial Statements, 2020 Form 10-K, page F-75-76

 

Indirect Economic Impacts

203-2

Significant indirect economic impacts

2020 Year in Review

Reporting Section - 2020 Year in Review

3, 4, 8

Procurement Practices

204-1

Proportion of spending on local suppliers

Not applicable

Biogen discloses this information only on a global level.

Principles, Policies & Positions

Supplier Diversity - Working With Us

5, 8

Tax

207-1

Approach to tax

This UK tax strategy applies to all Biogen UK entities and its publication is regarded as satisfying the statutory obligation under paragraph 19(2), Schedule 19 of the UK Finance Act 2016, for all the Biogen UK entities. The overall goal of Biogen’s tax policy is to support its business by maintaining a sustainable tax rate while complying with tax law and regulations and mitigating tax risks in the jurisdictions in which we operate.

 

Environment

Energy

302-1

Energy consumption within the organization

Environment Section – 2020 Year in Review

ESG Data Table – 2020 Year in Review

12

Water and Effluents

303-1

Interactions with water as a shared resource

Environment Section – 2020 Year in Review

ESG Data Table – 2020 Year in Review

2020 CDP Water Security disclosure 

6

303-3

Water withdrawal

Environment Section – 2020 Year in Review

ESG Data Table – 2020 Year in Review

2020 CDP Water Security disclosure 

6

303-4

Water discharge

Environment Section – 2020 Year in Review

ESG Data Table – 2020 Year in Review

2020 CDP Water Security disclosure 

6

303-5

Water consumption

Environment Section – 2020 Year in Review

ESG Data Table – 2020 Year in Review

2020 CDP Water Security disclosure 

6

Emissions

305-1

Direct (Scope 1) GHG emissions

Environment Section – 2020 Year in Review

ESG Data Table – 2020 Year in Review

2020 CDP Climate Change disclosure

7, 13

305-2

Energy indirect (Scope 2) GHG emissions

Environment Section – 2020 Year in Review

ESG Data Table – 2020 Year in Review

2020 CDP Climate Change disclosure

7, 13

305-3

Other indirect (Scope 3) GHG emissions

Environment Section – 2020 Year in Review

ESG Data Table – 2020 Year in Review

2020 CDP Climate Change disclosure

7, 13

305-5

Reduction of GHG emissions

Environment Section – 2020 Year in Review

ESG Data Table – 2020 Year in Review

2020 CDP Climate Change disclosure

7, 13

305-7

Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air emissions

ESG Data Table – 2020 Year in Review

 

Effluents and Waste

306-2

Management of significant waste-related impacts

Environment Section - 2020 Year in Review

ESG Data Table - 2020 Year in Review

12

Environmental Compliance

307-1

Non-compliance with environmental laws and regulations

There were no significant instances of non-compliance in 2020.

Principles, Policies & Positions

Item 1A., Risk Factors, 2020 Form 10-K, page 47

12

Supplier Environmental Assessments

308-1

New suppliers that were screened using environmental criteria

Environment Section – 2020 Year in Review 

12

308-2

Negative environmental impacts in the supply chain and actions taken

Environment Section – 2020 Year in Review

Reporting Section – 2020 Year in Review 

Item 1A., Risk Factors, 2020 Form 10-K, page 47

12

Social

Employment

401-1

New employee hires and employee turnover.

ESG Data Table - 2020 Year in Review

SASB Content Index

 

 

Occupational Health & Safety

403-1

Occupational health and safety management system

Our People Section - 2020 Year in Review

Environmental, Health and Safety Policy Statement 

3, 8

403-2

Hazard identification, risk assessment, and incident investigation

Our People Section - 2020 Year in Review

Environmental, Health and Safety Policy Statement 

3, 8

403-4

Worker participation, consultation, and communication on occupational health and safety

Our People Section - 2020 Year in Review

Environmental, Health and Safety Policy Statement 

3, 8

403-9

Work-related injuries

Our People Section - 2020 Year in Review

ESG Data Table - 2020 Year in Review 

Environmental, Health and Safety Policy Statement

3, 8

Diversity and Equal Opportunity

405-1

Diversity of governance bodies and employees

Our People Section - 2020 Year in Review 

ESG Data Table - 2020 Year in Review

Board of Directors

5

405-2

Ratio of basic salary and remuneration of women to men

Pay Equity Analysis, Our People Section – 2020 Year in Review

Confidentiality constraint

Biogen does not disclose externally any salary and wages related data except the Executive Compensation of the Executive Committee and Board of Directors

 

Local Communities

413-1

Operations with local community engagement, impact assessments, and development programs

Our People Section – 2020 Year in Review

Community Section – 2020 Year in Review

Grants Management and Strategic Giving 

3, 4

Supplier Social Assessment

414-1

New suppliers that were screened using social criteria

Reporting Section – 2020 Year in Review

Supplier Diversity – Working With Us

Code of Business Conduct (Values in Action) 

5, 8, 12

414-2

Negative social impacts in the supply chain and actions taken

Supplier Diversity – Working With Us

Code of Business Conduct (Values in Action)

Reporting Section – 2020 Year in Review 

5, 8, 12

Public Policy

415-1

Political contributions

Principles, Policies & Positions

Political Contributions Policy

Political Contributions Disclosure 

16

Customer Health and Safety

416-1

Assessment of the health and safety impacts of product and service categories

Patients Section – 2020 Year in Review

Pioneering Science Section – 2020 Year in Review

Principles, Policies & Positions 

Patient Safety 

Product Stewardship

3

416-2

Incidents of non-compliance concerning the health and safety impacts of products and services

Pioneering Science Section – 2020 Year in Review

Patient Safety 

3

Marketing and Labeling

417-1

Requirements for product and service information and labeling

Principles, Policies & Positions

Patient Safety

3, 16

417-2

Incidents of non-compliance concerning product and service information and labeling

There were no significant instances of non-compliance in 2020.

Principles, Policies & Positions

3

417-3

Incidents of non-compliance concerning marketing communications

There were no significant instances of non-compliance in 2020.

Principles, Policies & Positions

3